Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and...
Gespeichert in:
| Veröffentlicht in: | Nutrients 2022-06, Vol.14 (13), p.2683 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 13 |
| container_start_page | 2683 |
| container_title | Nutrients |
| container_volume | 14 |
| creator | Rendina, Domenico D Elia, Lanfranco Abate, Veronica Rebellato, Andrea Buondonno, Ilaria Succoio, Mariangela Martinelli, Fabio Muscariello, Riccardo De Filippo, Gianpaolo D Amelio, Patrizia Fallo, Francesco Strazzullo, Pasquale Faraonio, Raffaella |
| description | The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression. |
| doi_str_mv | 10.3390/nu14132683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9268320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2686177586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-827bec15c41a1b357b52815648139675fe371bdce7f80650594bdf86dd620fb33</originalsourceid><addsrcrecordid>eNpdkVtrFDEUx4MottS--AEk4ItIR5PJ5DI-FMrWdoXFLusFfAqZmTM2dSZZc1ncb-8MrbWalxM4v_M_lz9Czyl5w1hN3rpMK8pKodgjdFgSWRZCVOzxg_8BOo7xhsxPEinYU3TAuCJSieoQ_fpqkxmtw-f4UzIpxxO8MKGzfmdimwcT8MbGH3gdfG8HOMHGdXi0m49nRUnxCnYwRDxVL_dbCAlctDvAa5MsuBTf4Q3EPKSIfY_TNeDlt_XV-dwod_tn6ElvhgjHd_EIfbl4_3mxLFZXlx8WZ6uirYhIhSplAy3lbUUNbRiXDS8V5aJSlNVC8h6YpE3XguwVEZzwumq6XomuEyXpG8aO0Omt7jY3I0ygS8EMehvsaMJee2P1vxlnr_V3v9P1fNOSTAKv7gSC_5khJj3a2MIwGAc-Rz1hUlLJqnpCX_6H3vgc3LTeTAkqJVdiol7fUm3wMQbo74ehRM-e6r-eTvCLh-Pfo38cZL8B2CGbEg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2686177586</pqid></control><display><type>article</type><title>Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Rendina, Domenico ; D Elia, Lanfranco ; Abate, Veronica ; Rebellato, Andrea ; Buondonno, Ilaria ; Succoio, Mariangela ; Martinelli, Fabio ; Muscariello, Riccardo ; De Filippo, Gianpaolo ; D Amelio, Patrizia ; Fallo, Francesco ; Strazzullo, Pasquale ; Faraonio, Raffaella</creator><creatorcontrib>Rendina, Domenico ; D Elia, Lanfranco ; Abate, Veronica ; Rebellato, Andrea ; Buondonno, Ilaria ; Succoio, Mariangela ; Martinelli, Fabio ; Muscariello, Riccardo ; De Filippo, Gianpaolo ; D Amelio, Patrizia ; Fallo, Francesco ; Strazzullo, Pasquale ; Faraonio, Raffaella</creatorcontrib><description>The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu14132683</identifier><identifier>PMID: 35807864</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Calciferol ; Calcitriol ; Calcitriol - therapeutic use ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cholecalciferol - pharmacology ; Cholecalciferol - therapeutic use ; Cholesterol ; Clinical trials ; Coronary vessels ; Dietary Supplements ; Double-Blind Method ; Ethanol ; Evaluation ; Gene expression ; Health risks ; Heart Disease Risk Factors ; Heart failure ; HEK293 Cells ; Humans ; Hypertension ; Hypertension - drug therapy ; MicroRNAs ; miRNA ; Pathogenesis ; Patients ; Placebos ; Risk assessment ; Risk Factors ; Vein & artery diseases ; Vitamin D ; Vitamin D - therapeutic use ; Vitamin D Deficiency - drug therapy ; Vitamin deficiency ; Vitamins</subject><ispartof>Nutrients, 2022-06, Vol.14 (13), p.2683</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-827bec15c41a1b357b52815648139675fe371bdce7f80650594bdf86dd620fb33</citedby><cites>FETCH-LOGICAL-c406t-827bec15c41a1b357b52815648139675fe371bdce7f80650594bdf86dd620fb33</cites><orcidid>0000-0003-0085-0067 ; 0000-0002-1782-0211 ; 0000-0002-6563-8158 ; 0000-0002-7511-0226 ; 0000-0003-1313-5599 ; 0000-0002-4467-8337 ; 0000-0002-0331-0392</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268320/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268320/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35807864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rendina, Domenico</creatorcontrib><creatorcontrib>D Elia, Lanfranco</creatorcontrib><creatorcontrib>Abate, Veronica</creatorcontrib><creatorcontrib>Rebellato, Andrea</creatorcontrib><creatorcontrib>Buondonno, Ilaria</creatorcontrib><creatorcontrib>Succoio, Mariangela</creatorcontrib><creatorcontrib>Martinelli, Fabio</creatorcontrib><creatorcontrib>Muscariello, Riccardo</creatorcontrib><creatorcontrib>De Filippo, Gianpaolo</creatorcontrib><creatorcontrib>D Amelio, Patrizia</creatorcontrib><creatorcontrib>Fallo, Francesco</creatorcontrib><creatorcontrib>Strazzullo, Pasquale</creatorcontrib><creatorcontrib>Faraonio, Raffaella</creatorcontrib><title>Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.</description><subject>Calciferol</subject><subject>Calcitriol</subject><subject>Calcitriol - therapeutic use</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cholecalciferol - pharmacology</subject><subject>Cholecalciferol - therapeutic use</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Coronary vessels</subject><subject>Dietary Supplements</subject><subject>Double-Blind Method</subject><subject>Ethanol</subject><subject>Evaluation</subject><subject>Gene expression</subject><subject>Health risks</subject><subject>Heart Disease Risk Factors</subject><subject>Heart failure</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Placebos</subject><subject>Risk assessment</subject><subject>Risk Factors</subject><subject>Vein & artery diseases</subject><subject>Vitamin D</subject><subject>Vitamin D - therapeutic use</subject><subject>Vitamin D Deficiency - drug therapy</subject><subject>Vitamin deficiency</subject><subject>Vitamins</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkVtrFDEUx4MottS--AEk4ItIR5PJ5DI-FMrWdoXFLusFfAqZmTM2dSZZc1ncb-8MrbWalxM4v_M_lz9Czyl5w1hN3rpMK8pKodgjdFgSWRZCVOzxg_8BOo7xhsxPEinYU3TAuCJSieoQ_fpqkxmtw-f4UzIpxxO8MKGzfmdimwcT8MbGH3gdfG8HOMHGdXi0m49nRUnxCnYwRDxVL_dbCAlctDvAa5MsuBTf4Q3EPKSIfY_TNeDlt_XV-dwod_tn6ElvhgjHd_EIfbl4_3mxLFZXlx8WZ6uirYhIhSplAy3lbUUNbRiXDS8V5aJSlNVC8h6YpE3XguwVEZzwumq6XomuEyXpG8aO0Omt7jY3I0ygS8EMehvsaMJee2P1vxlnr_V3v9P1fNOSTAKv7gSC_5khJj3a2MIwGAc-Rz1hUlLJqnpCX_6H3vgc3LTeTAkqJVdiol7fUm3wMQbo74ehRM-e6r-eTvCLh-Pfo38cZL8B2CGbEg</recordid><startdate>20220628</startdate><enddate>20220628</enddate><creator>Rendina, Domenico</creator><creator>D Elia, Lanfranco</creator><creator>Abate, Veronica</creator><creator>Rebellato, Andrea</creator><creator>Buondonno, Ilaria</creator><creator>Succoio, Mariangela</creator><creator>Martinelli, Fabio</creator><creator>Muscariello, Riccardo</creator><creator>De Filippo, Gianpaolo</creator><creator>D Amelio, Patrizia</creator><creator>Fallo, Francesco</creator><creator>Strazzullo, Pasquale</creator><creator>Faraonio, Raffaella</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0085-0067</orcidid><orcidid>https://orcid.org/0000-0002-1782-0211</orcidid><orcidid>https://orcid.org/0000-0002-6563-8158</orcidid><orcidid>https://orcid.org/0000-0002-7511-0226</orcidid><orcidid>https://orcid.org/0000-0003-1313-5599</orcidid><orcidid>https://orcid.org/0000-0002-4467-8337</orcidid><orcidid>https://orcid.org/0000-0002-0331-0392</orcidid></search><sort><creationdate>20220628</creationdate><title>Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study</title><author>Rendina, Domenico ; D Elia, Lanfranco ; Abate, Veronica ; Rebellato, Andrea ; Buondonno, Ilaria ; Succoio, Mariangela ; Martinelli, Fabio ; Muscariello, Riccardo ; De Filippo, Gianpaolo ; D Amelio, Patrizia ; Fallo, Francesco ; Strazzullo, Pasquale ; Faraonio, Raffaella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-827bec15c41a1b357b52815648139675fe371bdce7f80650594bdf86dd620fb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Calciferol</topic><topic>Calcitriol</topic><topic>Calcitriol - therapeutic use</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cholecalciferol - pharmacology</topic><topic>Cholecalciferol - therapeutic use</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Coronary vessels</topic><topic>Dietary Supplements</topic><topic>Double-Blind Method</topic><topic>Ethanol</topic><topic>Evaluation</topic><topic>Gene expression</topic><topic>Health risks</topic><topic>Heart Disease Risk Factors</topic><topic>Heart failure</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Placebos</topic><topic>Risk assessment</topic><topic>Risk Factors</topic><topic>Vein & artery diseases</topic><topic>Vitamin D</topic><topic>Vitamin D - therapeutic use</topic><topic>Vitamin D Deficiency - drug therapy</topic><topic>Vitamin deficiency</topic><topic>Vitamins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rendina, Domenico</creatorcontrib><creatorcontrib>D Elia, Lanfranco</creatorcontrib><creatorcontrib>Abate, Veronica</creatorcontrib><creatorcontrib>Rebellato, Andrea</creatorcontrib><creatorcontrib>Buondonno, Ilaria</creatorcontrib><creatorcontrib>Succoio, Mariangela</creatorcontrib><creatorcontrib>Martinelli, Fabio</creatorcontrib><creatorcontrib>Muscariello, Riccardo</creatorcontrib><creatorcontrib>De Filippo, Gianpaolo</creatorcontrib><creatorcontrib>D Amelio, Patrizia</creatorcontrib><creatorcontrib>Fallo, Francesco</creatorcontrib><creatorcontrib>Strazzullo, Pasquale</creatorcontrib><creatorcontrib>Faraonio, Raffaella</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rendina, Domenico</au><au>D Elia, Lanfranco</au><au>Abate, Veronica</au><au>Rebellato, Andrea</au><au>Buondonno, Ilaria</au><au>Succoio, Mariangela</au><au>Martinelli, Fabio</au><au>Muscariello, Riccardo</au><au>De Filippo, Gianpaolo</au><au>D Amelio, Patrizia</au><au>Fallo, Francesco</au><au>Strazzullo, Pasquale</au><au>Faraonio, Raffaella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2022-06-28</date><risdate>2022</risdate><volume>14</volume><issue>13</issue><spage>2683</spage><pages>2683-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35807864</pmid><doi>10.3390/nu14132683</doi><orcidid>https://orcid.org/0000-0003-0085-0067</orcidid><orcidid>https://orcid.org/0000-0002-1782-0211</orcidid><orcidid>https://orcid.org/0000-0002-6563-8158</orcidid><orcidid>https://orcid.org/0000-0002-7511-0226</orcidid><orcidid>https://orcid.org/0000-0003-1313-5599</orcidid><orcidid>https://orcid.org/0000-0002-4467-8337</orcidid><orcidid>https://orcid.org/0000-0002-0331-0392</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6643 |
| ispartof | Nutrients, 2022-06, Vol.14 (13), p.2683 |
| issn | 2072-6643 2072-6643 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9268320 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Calciferol Calcitriol Calcitriol - therapeutic use Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - drug therapy Cholecalciferol - pharmacology Cholecalciferol - therapeutic use Cholesterol Clinical trials Coronary vessels Dietary Supplements Double-Blind Method Ethanol Evaluation Gene expression Health risks Heart Disease Risk Factors Heart failure HEK293 Cells Humans Hypertension Hypertension - drug therapy MicroRNAs miRNA Pathogenesis Patients Placebos Risk assessment Risk Factors Vein & artery diseases Vitamin D Vitamin D - therapeutic use Vitamin D Deficiency - drug therapy Vitamin deficiency Vitamins |
| title | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A48%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20Status,%20Cardiovascular%20Risk%20Profile,%20and%20miRNA-21%20Levels%20in%20Hypertensive%20Patients:%20Results%20of%20the%20HYPODD%20Study&rft.jtitle=Nutrients&rft.au=Rendina,%20Domenico&rft.date=2022-06-28&rft.volume=14&rft.issue=13&rft.spage=2683&rft.pages=2683-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu14132683&rft_dat=%3Cproquest_pubme%3E2686177586%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2686177586&rft_id=info:pmid/35807864&rfr_iscdi=true |